采用基于儿科方案改善老年急性淋巴细胞白血病患者的预后——一项前瞻性研究
这项挪威前瞻性 population-based 研究评估了基于儿科方案治疗65岁以上新诊断急性淋巴细胞白血病(ALL)的可行性与有效性。共入组52例患者(32例Ph阴性),中位随访3.2年,2年和5年总生存率分别为0.60(95%CI 0.46-0.74)和0.50(0.34-0.66)。结论认为该儿科方案耐受良好且有效,复发率低,长期生存率达50%。
要点
- 65岁以上新诊断ALL患者采用基于儿科方案,中位随访3.2年,5年总生存率为0.50(95%CI 0.34-0.66)。
- 52例入组患者中49例达缓解,缓解后仅6例复发,但6例在缓解期死亡、3例死于第二恶性肿瘤。
- Ph阴性患者接受未减量的聚乙二醇门冬酰胺酶(自第30天开始),Ph阳性患者接受伊马替尼治疗;体弱患者允许由治疗医生酌情减量。
核心结论
- 该基于儿科方案耐受良好且有效,复发率低,长期生存率达50%。
研究设计与样本
- 挪威前瞻性 population-based 研究,评估基于儿科方案治疗65岁以上新诊断ALL的可行性与有效性。
- 共入组52例患者,其中32例为Ph阴性;中位年龄70岁(范围65-82)。
- Ph阴性患者接受未减量的聚乙二醇门冬酰胺酶(自第30天开始),Ph阳性患者接受伊马替尼治疗;体弱患者允许由治疗医生酌情减量。
主要发现
- 49例达缓解,其中4例未接受进一步治疗并死亡;6例在缓解期死亡,3例死于第二恶性肿瘤。
- 其余36例患者中仅6例复发。
- 中位随访3.2年(四分位距1.3-6.3),2年和5年总生存率分别为0.60(95%CI 0.46-0.74)和0.50(95%CI 0.34-0.66)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Population data have shown that the prognosis for elderly patients with acute lymphoblastic leukaemia (ALL) is poor, even in the modern era and despite improvements in the outcome for younger patients. In this Norwegian prospective population-based study, the feasibility and effectiveness of a paediatric-based regimen in newly diagnosed patients above 65 years of age with ALL were assessed. Patients who were Philadelphia chromosome (Ph) negative were assigned to unmodified doses of pegylated asparaginase starting on day 30, while Ph-positive patients were treated with imatinib. For frail patients, dose reductions were allowed at the discretion of the treating physician. A total of 52 patients were enrolled, 32 of whom were Ph negative. The median age was 70 years (range 65-82). Forty-nine attained remission, of which four did not receive further treatment and died. Six patients died while in remission and three died from a second malignancy. Among the remaining 36 patients, only six relapsed. The 2-year and 5-year overall survival rates, with a median follow-up of 3.2 years (Interquartile range 1.3-6.3), were 0.60 (95% confidence interval 0.46-0.74) and 0.50 (0.34-0.66) respectively. In conclusion, this paediatric-based protocol was well tolerated and effective, with low relapse rates and 50% long-term survival.
引用
- Quist-Paulsen P, Horvei L, Dalgaard J, et al. Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study. Br J Haematol. 2025. PMID: 40947499. doi:10.1111/bjh.70159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。